<unk>  is an antineoplastic agent that is FDA approved for the treatment of as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to E. coli-derived<unk> araginase..   Common adverse reactions include hypersensitivity reactions, Pancreatitis, Glucose intolerance, Thrombosis and hemorrhage , systemic hypersensitivity, hyperglycemia, transaminases abnormal, fever, pancreatitis, local reactions, vomiting, nausea, thrombosis, hyperbilirubinemia, abdominal pain/discomfort, and diarrhea..
L-Asparaginase
Transaminase
D-amino acid dehydrogenase
Glucarpidase
Phosphoglucomutase
Pyruvate decarboxylase
Alglucerase
Formate dehydrogenase